You are here

P&T February 2013

Features

The Need to Reduce the Federal Deficit Puts Seniors and Providers on Notice
In view of changing Medicare payment policies, hospitals reassess pharmacy procedures.
Investigational Combinations for the Treatment Of BRAF-Mutated Metastatic Melanoma
The arrival of ipilimumab and vemurafenib has provided oncologists with new choices in a field in which options were slim and the prognosis was grim. Combination therapy may lead to an improved survival benefit.
Clinical and Economic Evaluation
A health economic model was constructed to predict the 5-year incidence of coronary heart disease and diabetes and associated costs after treatment in patients using second-generation antipsychotic agents.
Meeting Highlights

Drug therapies for multiple myeloma, mantle-cell lymphoma, and myelodysplastic syndromes

Meeting Highlights
Generic biologics (e.g., biosimilars) and medication safety related to Joint Commission hospital accreditation standards

Departments

Medication Errors
Drug orders can be accidentally omitted or misread if a scanner pulls too many pages through at once.
Prescription: Washington
A proposed FDA rule on unique device identification could complicate billing and bar-coding procedures for hospitals.

FDA approvals, drug indications, and updates

Cabozantinib (Cometriq) for metastatic medullary thyroid cancer; ponatinib (Iclusig) for two forms of leukemia; and raxibacumab for inhalational anthrax

Drug Forecast
Bapineuzumab for Alzheimer’s disease